Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1122461

registered interest
date	23/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of trends in the level of care and support available for women with breast cancer in (a) Merseyside, (b) North West England and (c) England in each of the last five years.
tabling member constituency	Liverpool, West Derby
tabling member printed	Stephen Twigg
uin	246436
answer	answer is ministerial correction date of answer 01/05/2019 answer text <p>The National Cancer Programme is committed to ensuring, where appropriate, every person diagnosed with cancer, including breast cancer, will have access to personalised care, including a needs assessment, a care plan and health and wellbeing information by 2021. This involves assessing the trends in the level of care and support available for all cancer patients, including breast cancer, at a Cancer Alliance level.</p><p>Cheshire and Merseyside Cancer Alliance have achieved full implementation of personalised stratified follow up for breast cancer patients, which includes supported self-management, holistic needs assessments, care planning and health and wellbeing information. Cheshire and Merseyside Cancer Alliance are also looking to improve personalised follow up for all cancers, including breast cancer, such as improving access to psychological care and access to care for, and prevention of, other consequences of treatment. The provision of support and care in the area covered by the Alliance has significantly improved (Alliance level results from the National Cancer Patients Experience Survey (2018)). Cancer patients in Cheshire and Merseyside rate their overall care as 8.9/10, with 92% reporting that they had access to a Clinical Nurse Specialist. For breast cancer patients, 98% of patients reported having access to a Clinical Nurse Specialist, and their overall rating of care was 9.1/10.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 01/05/2019 15:17:43 answering member 4455 label Biography information for Seema Kennedy
tabling member	167 label Biography information for Stephen Twigg

1110299

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when the NICE guidance on prescribing cannabis-based products for medical use will be published.
tabling member constituency	Liverpool, West Derby
tabling member printed	Stephen Twigg
uin	241989
answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is due to publish its guidelines on cannabis-based products for medicinal use in October 2019. The guidance will focus on four indications: chronic pain, intractable nausea and vomiting, treatment-resistant epilepsy and spasticity. It will be based on the best available international evidence and produced using NICE’s world-renowned process for delivering such guidelines.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/04/2019 16:58:48 answering member 4455 label Biography information for Seema Kennedy
tabling member	167 label Biography information for Stephen Twigg

1110302

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of NHS prescriptions for medical cannabis issued in each month since 1 November 2018.
tabling member constituency	Liverpool, West Derby
tabling member printed	Stephen Twigg
uin	241990
answer	answer is ministerial correction date of answer 11/04/2019 answer text <p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.</p><p> </p><p>Data on the number of items of cannabis-based medicines dispensed in NHS primary care in England from November 2018 to January 2019 has been published by the NHS Business Services Authority. Such data is published three months in arrears, and we expect information for February 2019 to be published shortly.</p><p> </p><p>The published data shows that the following number of items of Nabilone and Sativex (two cannabis-based medicines) were dispensed from November 2018 to January 2019:</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>November 2018</p></td><td><p>December 2018</p></td><td><p>January 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>46</p></td><td><p>49</p></td><td><p>44</p></td></tr><tr><td><p>Sativex</p></td><td><p>175</p></td><td><p>181</p></td><td><p>167</p></td></tr></tbody></table><p> </p><p>Data from the NHS Business Services Authority for between November 2018 and January 2019 shows that no prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in primary care in England during this time. We expect data for February 2019 to be available shortly.</p><p> </p><p>Unlike NHS primary care where all dispensed prescriptions are processed centrally, this is not the case for secondary care. This information is collected by a third party and not routinely published.</p><p> </p><p>94 patients have accessed Epidiolex though GW Pharma’s early access programmes ahead of a licensing decision by the European Medicines Agency.</p><p> </p><p>Intelligence from NHS England Controlled Drugs Accountable Officers is that, up until the end to March 2019, one private prescription has been issued for a cannabis-based product for medicinal use in secondary/tertiary care in England.</p><p> </p><p>Import notifications to the Medicines and Healthcare products Regulatory Agency indicate a greater number of supplies. We are therefore cross-checking to ensure that information on the number of prescriptions for cannabis-based products for medicinal use aligns across the different data sources.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/04/2019 16:56:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	167 label Biography information for Stephen Twigg

1110308

registered interest
date	08/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV infection: Ethnic Groups and Females
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his department has made an assessment of the potential merits of developing a public health campaign to reduce late diagnosis among (a) BME and (b) female people living with HIV.
tabling member constituency	Liverpool, West Derby
tabling member printed	Stephen Twigg
uin	241993
answer	answer is ministerial correction date of answer 12/04/2019 answer text <p>Reducing late diagnoses of HIV amongst black and minority ethnic (BAME) people and women living with HIV is already an aim of Public Health England’s (PHE) HIV prevention programmes.</p><p> </p><p>HIV Prevention England, the national HIV prevention campaign funded by PHE and delivered by Terrence Higgins Trust, aims to promote HIV testing to reduce undiagnosed and late HIV diagnoses in Black African communities (men and women), men who have sex with men, and other groups in which there is a higher or emerging burden of infection. Further information is available to view at the following link:</p><p> </p><p><a href="https://www.hivpreventionengland.org.uk/" target="_blank">https://www.hivpreventionengland.org.uk/</a></p><p> </p><p>PHE also runs the HIV Innovation Fund which supports volunteer organisations leading new approaches to HIV prevention and focuses on engaging at-risk or under-served communities. Since 2015, the HIV Innovation Fund has supported 16 projects specifically targeted at Black African/other BAME people, and three targeted at women. Projects funded in 2018 are available to view the following link:</p><p> </p><p><a href="https://www.gov.uk/government/news/innovative-hiv-prevention-projects-reached-170000-people-in-2018" target="_blank">https://www.gov.uk/government/news/innovative-hiv-prevention-projects-reached-170000-people-in-2018</a></p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 12/04/2019 14:13:12 answering member 4455 label Biography information for Seema Kennedy
tabling member	167 label Biography information for Stephen Twigg